NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the “Class Period”), of the important November 17, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

公司事件概述 - 一家律师事务所正代表在2023年12月27日至2025年5月6日期间遭受损失的投资者，对Cytokinetics公司提起联邦证券集体诉讼 [1] - 诉讼指控公司管理层就新药Aficamten的申请时间表及审批流程做出了重大虚假和误导性陈述 [2] - 诉讼中提及的寻求首席原告资格的截止日期为2025年11月17日 [1] 具体指控内容 - 公司曾向投资者表示，基于2025年9月26日的处方药使用者费用法案日期，预计美国FDA将在2025年下半年批准Aficamten的新药申请 [2] - 公司未能披露其未提交风险评估与减灾策略可能延迟监管流程的重大风险 [2] - 2025年5月6日，公司在财报电话会上透露，在与FDA进行多次新药申请前会议后，选择在不包含REMS的情况下提交申请，而依赖标签和自愿教育材料 [3] - 这一行为证实了管理层知晓潜在的REMS要求，但仍在初始申请中故意省略，从而误导了投资者对监管时间表的预期 [3] 事件影响 - 指控称，由于公司的虚假和误导性陈述，集体诉讼成员以被人为抬高的价格购买了公司普通股，并在真相揭露后遭受了重大损失 [4]

SO WHAT: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. WHAT TO DO NEXT: To join the Cyt ...

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cytokinet ...

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Incorporated, (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to dis ...

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, ...

NEW YORK CITY and NEW ORLEANS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pe ...

, /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Cytokinetics, Inc. (NASDAQ: CYTK) securities between December 27, 2023 and May 6, 2025. Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. For mor ...

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cytokine ...